Antiretroviral News and Research

RSS

Mylan releases generic version of Boniva Injection

Mylan Inc. today announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes, which is the generic version of Hoffmann-La Roche's Boniva Injection.

5 Sep 2014

Study: Innovative approaches required to decrease HIV transmission among Russian

Results of a new study conducted in St. Petersburg, Russia, show that decreasing HIV transmission among Russian HIV-infected drinkers will require creative and innovative approaches.

5 Sep 2014

Case Western Reserve scientists discover leaky gut as source of non-AIDS complications

Human immunodeficiency virus (HIV) infection is no longer a fatal condition, thanks to newer medications inhibiting the retrovirus, but a puzzling phenomenon has surfaced among these patients — non-AIDS complications. Scientists at Case Western Reserve University School of Medicine have resolved the mystery with their discovery of the leaky gut as the offender.

4 Sep 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Aug 2014

FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

Mylan Inc. today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration.

28 Aug 2014

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.

23 Aug 2014

Mylan launches Potassium Chloride Extended-release Tablets

Mylan Inc. today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con.

22 Aug 2014

Researchers find that same desire for intimacy is strong predictor for PrEp HIV prevention

Men in steady same-sex relationships where both partners are HIV negative will often forgo condoms out of a desire to preserve intimacy, even if they also have sex outside the relationship.

20 Aug 2014

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs.

19 Aug 2014

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.

11 Aug 2014

EGPAF applauds new licensing agreement to improve access to HIV medication for children

The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication.

26 Jul 2014

SIV can be entrenched in tissues before virus is detectable in blood plasma

Scientists have generally believed that HIV and its monkey equivalent, SIV, gain a permanent foothold in the body very early after infection, making it difficult to completely eliminate the virus even after antiretroviral therapy has controlled it.

22 Jul 2014

EGPAF experts to deliver presentations at AIDS 2014

Experts from the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) will give oral presentations, moderate conference events, and exhibit a variety of educational posters and abstracts related to ending AIDS in children.

21 Jul 2014

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients.

21 Jul 2014

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS.

21 Jul 2014

HIV self-testing increases proportion of adults initiating antiretroviral therapy

Among adults in the African country of Malawi offered HIV self-testing, optional home initiation of care compared with standard HIV care resulted in a significant increase in the proportion of adults initiating antiretroviral therapy, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS.

21 Jul 2014

New guidelines integrate biomedical advances and behavioral interventions for HIV people

In an innovative approach to HIV prevention, an interdisciplinary group of experts has come together for the first time to lay out a framework of best practices to optimize the role of the clinician in achieving an AIDS-free generation.

21 Jul 2014

Annual HIV diagnosis rate in the U.S. decreases more than 30%: Study

The annual HIV diagnosis rate in the U.S. decreased more than 30 percent from 2002-2011, with declines observed in several key populations, although increases were found among certain age groups of men who have sex with men, especially young men, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS.

21 Jul 2014

Discovery presents new challenges for HIV eradication efforts

The most critical barrier for curing HIV-1 infection is the presence of the viral reservoir, the cells in which the HIV virus can lie dormant for many years and avoid elimination by antiretroviral drugs. Very little has been known about when and where the viral reservoir is established during acute HIV-1 infection, or the extent to which it is susceptible to early antiretroviral therapy (ART).

21 Jul 2014

Large proportion of PLHA in US are not sufficiently engaged in care and not taking ART

Regular attendance at HIV primary care visits and high adherence to antiretroviral therapy (ART) are vital for people living with HIV/AIDS (PLHA), as these health behaviors lead to lowered rates of morbidity and mortality, increased quality of life, and reducing the risk of HIV transmission to others.

18 Jul 2014

Antiretroviral News and Research

Mylan releases generic version of Boniva Injection

Study: Innovative approaches required to decrease HIV transmission among Russian

Case Western Reserve scientists discover leaky gut as source of non-AIDS complications

iCo Therapeutics reports financial results for second quarter 2014

FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

Mylan launches Potassium Chloride Extended-release Tablets

Researchers find that same desire for intimacy is strong predictor for PrEp HIV prevention

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

EGPAF applauds new licensing agreement to improve access to HIV medication for children

SIV can be entrenched in tissues before virus is detectable in blood plasma

EGPAF experts to deliver presentations at AIDS 2014

Drug for reduction of abdominal fat in HIV patients may also reduce fatty liver disease

Growth hormone reduces liver fat in HIV-infected patients with excess abdominal fat

HIV self-testing increases proportion of adults initiating antiretroviral therapy

New guidelines integrate biomedical advances and behavioral interventions for HIV people

Annual HIV diagnosis rate in the U.S. decreases more than 30%: Study

Discovery presents new challenges for HIV eradication efforts

Large proportion of PLHA in US are not sufficiently engaged in care and not taking ART

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News